Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective
CPT Pharmacometrics Syst Pharmacol
.
2023 May;12(5):556-559.
doi: 10.1002/psp4.12906.
Epub 2023 Jan 11.
Authors
Efthymios Manolis
1
,
Alfredo García-Arieta
2
,
Anders Lindahl
3
,
Evangelos Kotzagiorgis
1
,
Jobst Limberg
4
,
Øyvind Holte
5
,
Paulo Paixao
6
,
Carolien Versantvoort
7
,
Flora Musuamba Tshinanu
8
,
Kevin Blake
1
,
Michiel Van Den Heuvel
7
Affiliations
1
European Medicines Agency, Amsterdam, The Netherlands.
2
Spanish Agency of Medicines and Medical Devices, Madrid, Spain.
3
Swedish Medical Products Agency, Uppsala, Sweden.
4
Federal Institute of Drugs and Medical Devises, Bonn, Germany.
5
Norwegian Medicines Agency, Oslo, Norway.
6
INFARMED - National Authority of Medicines and Health Products, Lisbon, Portugal.
7
Medicines Evaluation Board, Utrecht, The Netherlands.
8
Federal Agency for Medicines and Health Products, Brussels, Belgium.
PMID:
36628987
PMCID:
PMC10196408
DOI:
10.1002/psp4.12906
No abstract available
MeSH terms
Drug Approval*
Drugs, Generic*
Humans
Therapeutic Equivalency
Substances
Drugs, Generic